- H1 outpatient prescription sales reaches KRW 535.3 billion… Emphasis on ‘product’ sales over ‘goods’
- ‘Rosuzet’ tops KRW 110 billion in H1 sales alone, driven by family brands like ‘Amosartan’ and ‘Esomezol’
[by Kang, In Hyo] Hanmi Pharmaceutical (hereinafter referred to as Hanmi Pharm) secured to leading position in outpatient prescription sales in Korea during the first half of the year, driven by the steady growth of its in-house developed drugs. Should this trend persist in H2, the company is projected to maintain its top spot for an eighth consecutive year in outpatient prescription sales.
According to data released on July 28 by UBIST, a pharmaceutical market research institute, 카지노 바카라 Pharm achieved outpatients prescription sales of KRW 535.3 billion (approximately USD 384.6 million) in the first half of this year, marking a 3.1% increase compared to the same period last year. this growth was primarily attributed to the strong performance of its self-developed drug portfolios, including the ‘Amosartan Family’ and the ‘Esomezol Family’. In particular, the company reported that ten of its individual products each surpassed KRW 10 billion in sales during H1, underscoring its leadership in the Korean prescription drug market.
카지노 바카라 Pharm has retained the top position in annual outpatient prescription sales for seven consecutive years since first achieving this distinction in 2018. Given its strong performance in the first half of this year, it is highly likely that the company will secure the top spot for an eighth consecutive year. “This achievement is significant in that it stems from ‘product sales’ developed using 카지노 바카라’s proprietary technology, rather than from the distribution of drugs licensed from multinational pharmaceutical companies,” said Park Jae-hyun, CEO of 카지노 바카라 Pharm. “The profits generated from these self-developed products are reinvested into research and development (R&D), further solidifying 카지노 바카라’s ‘sustainable R&D virtuous cycle model.’”
The highest-performing product in the first half of this year was ‘Rosuzet,’ a combination therapy for the treatment of dyslipidemia, which recorded outpatient prescription sales of KRW 110.3 billion (approximately USD 79.2 million), an increase of 10% compared to the same period in 2024. Having become the first domestically developed drug to surpass KRW 200 billion in annual prescription sales in the previous year, Rosuzet reaffirmed its market dominance by exceeding KRW 100 billion in sales in just the first half of this year.
Following Rosuzet, the Amosartan family (Amosartan, Amosartan Plus, Amosartan Q, Amosartan XQ), a combination therapy for hypertension, recorded prescription sales of KRW 72.1 billion. The Esomezol family (Esomezol Capsule, Esomezol DR, Esomezol Plus) for the treatment of gastroesophageal reflux disease, ranked next with KRW 31.7 billion in sales. 카지노 바카라 Pharm further emphasized its steady growth in various therapeutic areas, as evidenced by the strong performance of additional products: 카지노 바카라 Tams Family (benign prostatic hypertrophy treatment), KRW 22.4 billion, PalPal (erectile dysfunction treatment), KRW 19 billion, Amlodipine (hypertension treatment), KRW 12.3 billion, Naxozol (anti-inflammatory analgesic), KRW 12.3 billion, Gugutams (erectile dysfunction treatment), KRW 11.3 billion, and Pidogul (antithrombotic agent), KRW 10.1 billion.
"Through sustained R&D and a marketing strategy centered on field performance, our company has secured a strong reputation as a trusted brand among healthcare professionals and patients across various disease groups," stated Park Myung-hee, Head of 카지노 바카라 Pharm's Domestic Business Division. "In the second half of the year, we will continue to contribute to public health through innovative combination therapies and uphold our responsibilities as a leading pharmaceutical enterprise," she added.
Conversely, 카지노 바카라 Pharm is reinforcing its strategic focus on combination therapies targeting hypertension, dyslipidemia, and diabetes, while simultaneously expanding its brand presence in a broad spectrum of therapeutic areas, including circulatory, urological, and bone metabolism disorders.
